Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/ncomms12731 http://scihub22266oqcxt.onion/10.1038/ncomms12731 C5025526!5025526 !27605062     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27605062 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27605062 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Commun 2016 ; 7 (ä): 12731 Nephropedia Template TP {{tp|p=27605062 |t=2016. Broad activation of latent HIV-1 in vivo |pdf=|usr=}}{{27605062 }} gab.com Text Broad activation of latent HIV-1 in vivo JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=27605062 #FOAvip The 'shock and kill' approach to cure human immunodeficiency virus (HIV) includes transcriptional induction of latent HIV-1 proviruses using latency-reversing agents (LRAs) with targeted immunotherapy to purge infected cells. The administration of LRAs (panobinostat or vorinostat) to HIV-1-infected individuals on antiretroviral therapy induces a significant increase in cell-associated unspliced (CA-US) HIV-1 RNA from CD4(+) T cells. However, it is important to discern whether the increases in CA-US HIV-1 RNA are due to limited or broad activation of HIV-1 proviruses. Here we use single-genome sequencing to find that the RNA transcripts observed following LRA administration are genetically diverse, indicating activation of transcription from an extensive range of proviruses. Defective sequences are more frequently found in CA HIV-1 RNA than in HIV-1 DNA, which has implications for developing an accurate measure of HIV-1 reservoir size. Our findings provide insights into the effects of panobinostat and vorinostat as LRAs for latent HIV-1. Twit Text FOAVip Broad activation of latent HIV-1 in vivo ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=27605062 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27605062 #FOAvip English Wikipedia <ref>{{Cite pmid|27605062 }}</ref> Broad activation of latent HIV-1 in vivo #MMPMID27605062 Barton K ; Hiener B ; Winckelmann A ; Rasmussen TA ; Shao W ; Byth K ; Lanfear R ; Solomon A ; McMahon J ; Harrington S ; Buzon M ; Lichterfeld M ; Denton PW ; Olesen R ; Østergaard L ; Tolstrup M ; Lewin SR ; Søgaard OS ; Palmer S Nat Commun 2016[Sep]; 7 (ä): 12731 PMID27605062 show ga The 'shock and kill' approach to cure human immunodeficiency virus (HIV) includes transcriptional induction of latent HIV-1 proviruses using latency-reversing agents (LRAs) with targeted immunotherapy to purge infected cells. The administration of LRAs (panobinostat or vorinostat) to HIV-1-infected individuals on antiretroviral therapy induces a significant increase in cell-associated unspliced (CA-US) HIV-1 RNA from CD4(+) T cells. However, it is important to discern whether the increases in CA-US HIV-1 RNA are due to limited or broad activation of HIV-1 proviruses. Here we use single-genome sequencing to find that the RNA transcripts observed following LRA administration are genetically diverse, indicating activation of transcription from an extensive range of proviruses. Defective sequences are more frequently found in CA HIV-1 RNA than in HIV-1 DNA, which has implications for developing an accurate measure of HIV-1 reservoir size. Our findings provide insights into the effects of panobinostat and vorinostat as LRAs for latent HIV-1. |Adult [MESH] |Anti-HIV Agents/administration & dosage/*therapeutic use [MESH] |CD4-Positive T-Lymphocytes/virology [MESH] |DNA, Viral/*genetics [MESH] |Drug Administration Schedule [MESH] |HIV Infections/virology [MESH] |HIV-1/*genetics [MESH] |Humans [MESH] |Hydroxamic Acids/administration & dosage/therapeutic use [MESH] |Indoles/administration & dosage/therapeutic use [MESH] |Middle Aged [MESH] |Panobinostat [MESH] |RNA, Viral/*genetics [MESH] |Viremia [MESH] |Virus Latency [MESH]Broad activation of latent HIV-1 in vivo (epmc).pdf DeepDyve Pubget Overpricing